journal
MENU ▼
Read by QxMD icon Read
search

PharmacoEconomics

journal
https://www.readbyqxmd.com/read/28550592/certolizumab-pegol-for-treating-rheumatoid-arthritis-following-inadequate-response-to-a-tnf-%C3%AE-inhibitor-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#1
REVIEW
Iñigo Bermejo, Matt Stevenson, Rachel Archer, John W Stevens, Edward Goka, Mark Clowes, David L Scott, Adam Young
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (UCB Pharma) of certolizumab pegol (CZP; Cimzia(®)) to submit evidence of its clinical and cost effectiveness for the treatment of rheumatoid arthritis (RA) following inadequate response to a tumour necrosis factor-α inhibitor (TNFi). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG)...
May 26, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28536955/using-discrete-choice-experiments-to-inform-the-benefit-risk-assessment-of-medicines-are-we-ready-yet
#2
Caroline M Vass, Katherine Payne
There is emerging interest in the use of discrete choice experiments as a means of quantifying the perceived balance between benefits and risks (quantitative benefit-risk assessment) of new healthcare interventions, such as medicines, under assessment by regulatory agencies. For stated preference data on benefit-risk assessment to be used in regulatory decision making, the methods to generate these data must be valid, reliable and capable of producing meaningful estimates understood by decision makers. Some reporting guidelines exist for discrete choice experiments, and for related methods such as conjoint analysis...
May 23, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28534254/the-cost-of-relapse-in-schizophrenia
#3
REVIEW
Mark Pennington, Paul McCrone
INTRODUCTION: Schizophrenia is a chronic and debilitating mental illness characterised by periods of relapse that require resource intensive management. Quantifying the cost of relapse is central to the evaluation of the cost effectiveness of treating schizophrenia. OBJECTIVES: We aimed to undertake a comprehensive search of the available literature on the cost of relapse. METHODS: We performed a search on multiple databases (MEDLINE, Embase, PsycINFO and Health Management Information Consortium) for any study reporting a cost of relapse or data from which such a cost could be calculated...
May 22, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28528523/sharing-is-caring-the-case-for-company-level-collaboration-in-pharmacoeconomic-modelling
#4
LETTER
Anthony J Hatswell, Fleur Chandler
No abstract text is available yet for this article.
May 20, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28488257/a-comparison-of-four-software-programs-for-implementing-decision-analytic-cost-effectiveness-models
#5
REVIEW
Chase Hollman, Mike Paulden, Petros Pechlivanoglou, Christopher McCabe
The volume and technical complexity of both academic and commercial research using decision analytic modelling has increased rapidly over the last two decades. The range of software programs used for their implementation has also increased, but it remains true that a small number of programs account for the vast majority of cost-effectiveness modelling work. We report a comparison of four software programs: TreeAge Pro, Microsoft Excel, R and MATLAB. Our focus is on software commonly used for building Markov models and decision trees to conduct cohort simulations, given their predominance in the published literature around cost-effectiveness modelling...
May 9, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28477220/defining-and-measuring-the-affordability-of-new-medicines-a-systematic-review
#6
REVIEW
Fernando Antoñanzas, Robert Terkola, Paul M Overton, Natalie Shalet, Maarten Postma
BACKGROUND: In many healthcare systems, affordability concerns can lead to restrictions on the use of expensive efficacious therapies. However, there does not appear to be any consensus as to the terminology used to describe affordability, or the thresholds used to determine whether new drugs are affordable. OBJECTIVES: The aim of this systematic review was to investigate how affordability is defined and measured in healthcare. METHODS: MEDLINE, EMBASE and EconLit databases (2005-July 2016) were searched using terms covering affordability and budget impact, combined with definitions, thresholds and restrictions, to identify articles describing a definition of affordability with respect to new medicines...
May 5, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28474299/evaluation-of-healthcare-interventions-and-big-data-review-of-associated-data-issues
#7
Carl V Asche, Brian Seal, Kristijan H Kahler, Elisabeth M Oehrlein, Meredith Greer Baumgartner
Although the analysis of 'big data' holds tremendous potential to improve patient care, there remain significant challenges before it can be realized. Accuracy and completeness of data, linkage of disparate data sources, and access to data are areas that require particular focus. This article discusses these areas and shares strategies to promote progress. Improvement in clinical coding, innovative matching methodologies, and investment in data standardization are potential solutions to data validation and linkage problems...
May 4, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28470594/how-to-appropriately-extrapolate-costs-and-utilities-in-cost-effectiveness-analysis
#8
Laura Bojke, Andrea Manca, Miqdad Asaria, Ronan Mahon, Shijie Ren, Stephen Palmer
Costs and utilities are key inputs into any cost-effectiveness analysis. Their estimates are typically derived from individual patient-level data collected as part of clinical studies the follow-up duration of which is often too short to allow a robust quantification of the likely costs and benefits a technology will yield over the patient's entire lifetime. In the absence of long-term data, some form of temporal extrapolation-to project short-term evidence over a longer time horizon-is required. Temporal extrapolation inevitably involves assumptions regarding the behaviour of the quantities of interest beyond the time horizon supported by the clinical evidence...
May 3, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28456972/verification-of-decision-analytic-models-for-health-economic-evaluations-an-overview
#9
Erik J Dasbach, Elamin H Elbasha
Decision-analytic models for cost-effectiveness analysis are developed in a variety of software packages where the accuracy of the computer code is seldom verified. Although modeling guidelines recommend using state-of-the-art quality assurance and control methods for software engineering to verify models, the fields of pharmacoeconomics and health technology assessment (HTA) have yet to establish and adopt guidance on how to verify health and economic models. The objective of this paper is to introduce to our field the variety of methods the software engineering field uses to verify that software performs as expected...
April 29, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28455834/does-the-public-prefer-health-gain-for-cancer-patients-a-systematic-review-of-public-views-on-cancer-and-its-characteristics
#10
REVIEW
Liz Morrell, Sarah Wordsworth, Sian Rees, Richard Barker
BACKGROUND: Policies such as the Cancer Drugs Fund in England assumed a societal preference to fund cancer care relative to other conditions, even if that resulted in lower health gain for the population overall. OBJECTIVE: The aim of this study was to investigate the evidence for such a preference among the UK public. METHODS: The MEDLINE, PubMed and Econlit electronic databases were searched for studies relating to preferences for prioritising cancer treatment, as well as studies relating to preferences for the characteristics of cancer (severity of disease, end-of-life)...
April 29, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28432642/emerging-use-of-early-health-technology-assessment-in-medical-product-development-a-scoping-review-of-the-literature
#11
REVIEW
Maarten J IJzerman, Hendrik Koffijberg, Elisabeth Fenwick, Murray Krahn
Early health technology assessment is increasingly being used to support health economic evidence development during early stages of clinical research. Such early models can be used to inform research and development about the design and management of new medical technologies to mitigate the risks, perceived by industry and the public sector, associated with market access and reimbursement. Over the past 25 years it has been suggested that health economic evaluation in the early stages may benefit the development and diffusion of medical products...
April 21, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28391508/response-to-letter-to-the-editor-regarding-abiraterone-acetate-for-the-treatment-of-chemotherapy-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#12
LETTER
Bram L T Ramaekers, Rob Riemsma, Florian Tomini, Thea van Asselt, Sohan Deshpande, Steven Duffy, Nigel Armstrong, Johan L Severens, Jos Kleijnen, Manuela A Joore
No abstract text is available yet for this article.
April 8, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28390016/comment-on-abiraterone-acetate-for-the-treatment-of-chemotherapy-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer-an-evidence-review-group-perspective-of-an-nice-single-technology-appraisal
#13
LETTER
Odette Reifsnider, Fiona Hall, Sonja Sorensen, Irina Proskorovsky, Isabelle Girod, Jennifer Lee
No abstract text is available yet for this article.
April 8, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28378193/regression-based-approaches-to-patient-centered-cost-effectiveness-analysis
#14
Daisuke Goto, Ya-Chen Tina Shih, Pascal Lecomte, Melvin Olson, Chukwukadibia Udeze, Yujin Park, C Daniel Mullins
Achieving comprehensive patient centricity in cost-effectiveness analyses (CEAs) requires a statistical approach that accounts for patients' preferences and clinical and demographic characteristics. Increased availability and accessibility of patient-level health-related utility data from clinical trials or observational database provide enhanced opportunities to conduct more patient-centered CEA. Regression-based approaches that incorporate patient-level data hold great promise for enhancing CEAs to be more patient centered; this paper provides guidance regarding two CEA approaches that apply regression-based approaches utilizing patient-level health-related utility and costs data...
April 4, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28374325/discrete-choice-experiments-a-guide-to-model-specification-estimation-and-software
#15
Emily Lancsar, Denzil G Fiebig, Arne Risa Hole
We provide a user guide on the analysis of data (including best-worst and best-best data) generated from discrete-choice experiments (DCEs), comprising a theoretical review of the main choice models followed by practical advice on estimation and post-estimation. We also provide a review of standard software. In providing this guide, we endeavour to not only provide guidance on choice modelling but to do so in a way that provides a 'way in' for researchers to the practicalities of data analysis. We argue that choice of modelling approach depends on the research questions, study design and constraints in terms of quality/quantity of data and that decisions made in relation to analysis of choice data are often interdependent rather than sequential...
April 3, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28342114/using-parameter-constraints-to-choose-state-structures-in-cost-effectiveness-modelling
#16
Howard Thom, Chris Jackson, Nicky Welton, Linda Sharples
BACKGROUND: This article addresses the choice of state structure in a cost-effectiveness multi-state model. Key model outputs, such as treatment recommendations and prioritisation of future research, may be sensitive to state structure choice. For example, it may be uncertain whether to consider similar disease severities or similar clinical events as the same state or as separate states. Standard statistical methods for comparing models require a common reference dataset but merging states in a model aggregates the data, rendering these methods invalid...
March 24, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28342113/crizotinib-for-untreated-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#17
REVIEW
Philip Morgan, Nerys Woolacott, Mousumi Biswas, Teumzghi Mebrahtu, Melissa Harden, Robert Hodgson
As part of the National Institute for Health and Care Excellence (NICE) single technology appraisal process, the manufacturer of crizotinib submitted evidence on the clinical and cost effectiveness of crizotinib in untreated anaplastic lymphoma kinase-positive (ALK-positive) non-small-cell lung cancer (NSCLC). Crizotinib has previously been assessed by NICE for patients with previously treated ALK-positive NSCLC (TA 296). It was not approved in this previous appraisal, but had been made available through the cancer drugs fund...
March 24, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28342112/an-investigation-of-the-overlap-between-the-icecap-a-and-five-preference-based-health-related-quality-of-life-instruments
#18
Lidia Engel, Duncan Mortimer, Stirling Bryan, Scott A Lear, David G T Whitehurst
BACKGROUND: The ICEpop CAPability measure for Adults (ICECAP-A) is a measure of capability wellbeing developed for use in economic evaluations. It was designed to overcome perceived limitations associated with existing preference-based instruments, where the explicit focus on health-related aspects of quality of life may result in the failure to capture fully the broader benefits of interventions and treatments that go beyond health. The aim of this study was to investigate the extent to which preference-based health-related quality of life (HRQoL) instruments are able to capture aspects of capability wellbeing, as measured by the ICECAP-A...
March 24, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28337720/defining-value-the-need-for-a-longer-broader-view
#19
LETTER
Tomas J Philipson, Sachin Kamal-Bahl, Anupam B Jena
No abstract text is available yet for this article.
March 23, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28337719/an-early-health-economic-analysis-of-the-potential-cost-effectiveness-of-an-adherence-intervention-to-improve-outcomes-for-patients-with-cystic-fibrosis
#20
Paul Tappenden, Susannah Sadler, Martin Wildman
BACKGROUND: Cystic fibrosis (CF) negatively impacts upon health-related quality of life and survival. Adherence to nebulised treatments is low; improving adherence is hypothesised to reduce rates of exacerbation requiring intravenous antibiotics and lung function decline. OBJECTIVE: A state transition model was developed to assess the cost effectiveness of an intervention aimed at increasing patient adherence to nebulised and inhaled antibiotics compared with current CF care, in advance of the forthcoming CFHealthHub randomised controlled trial (RCT)...
March 23, 2017: PharmacoEconomics
journal
journal
31126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"